ClinicalTrials.gov
public full text
Public Domain
A Phase I Trial Using Combination Irinotecan and Thalidomide for Recurrent CNS Tumors
The study will try to answer these questions: 1. What is the highest dose of thalidomide brain cancer patients can receive safely in combination with irinotecan? 2. How well does this combination work to shrink brain tumors, and how long do responses to treatment last? 3. What side effects does the combination of drugs cause? 4. How does treatment affect patients' quality of life (how they feel and what activities they are able to do)?
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Irinotecan Plus Carmustine in Treating Patients With Recurrent Primary Malignant Glioma#1487491
- Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I#1365439
- Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma#1440318
- Irinotecan in Treating Patients With Recurrent Malignant Glioma#1453060
- Thalidomide in Treating Patients With Relapsed Chronic Lymphocytic Leukemia#1075333
Record · ID 1495982
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive